Revolution Medicines, Inc. (RVMD)
NASDAQ: RVMD · Real-Time Price · USD
166.87
-5.42 (-3.15%)
At close: Nov 16, 2026, 4:00 PM EST
167.80
+0.93 (0.56%)
After-hours: Nov 16, 2026, 7:57 PM EST

Revolution Medicines Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
197.56--11.5835.3829.39
Revenue Growth
----67.27%20.38%-31.62%
Gross Profit
-1,254-987.33-592.23-407.86-217.69-157.56
Operating Income
-1,685-1,182-689.52-475.99-258.28-188.01
Net Income
-1,871-1,131-600.09-436.37-248.71-187.09
Earnings Per Share
-9.14-5.95-3.58-3.86-3.08-2.57
EPS Growth
------

Cash & Debt

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
3,6512,0262,2891,853644.94577.05
Total Debt
1,211427.15135.8487.9464.2166.63
Net Cash (Debt)
2,4401,5992,1531,765580.74510.42
Net Cash Growth
60.89%-25.77%22.01%203.93%13.78%25.08%
Net Cash Per Share
11.928.4112.8415.607.207.01

Cash Flow & CapEx

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-1,431-897.74-557.44-350.57-224.4-147.18
Capital Expenditures
-9.45-15.99-10.31-7.73-10.82-6.53
Free Cash Flow
-1,441-913.73-567.74-358.3-235.22-153.71
Free Cash Flow Growth
------

Margins

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
------
Operating Margin
-852.98%---4110.41%-730.01%-639.70%
Pretax Margin
-948.02%---3798.71%-704.14%-636.58%
Profit Margin
-946.82%---3768.28%-702.95%-636.58%
FCF Margin
-729.31%---3094.14%-664.83%-522.99%

Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingNov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
182.67--407.5859.7863.11